Prevalence of Subclinical Hypothyroidism and Its Association with Noninvasive Fibrosis Scores in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
Author:
- 9 June 2026
- journal article
- Published by Osmangazi Journal of Medicine in OSMANGAZİ JOURNAL OF MEDICINE
- Vol. 48 (4) , 646-653
Abstract
Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely related to obesity, insulin resistance, and diabetes mellitus. Thyroid hormones play a key role in lipid and glucose metabolism, and subclinical hypothyroidism has been suggested to contribute to metabolic disturbances. This study aimed to determine the prevalence of subclinical hypothyroidism in patients with MASLD and evaluate its association with noninvasive fibrosis scores. This retrospective cross-sectional study included 200 adult patients diagnosed with MASLD. Patients were classified as having subclinical hypothyroidism or euthyroid status based on thyroid function tests. Demographic characteristics, metabolic parameters, and laboratory findings were recorded. Fibrosis risk was assessed using the Fibrosis-4 (FIB-4) index and the non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS). Group comparisons, correlation analyses, and multivariable logistic regression were performed. The mean age of the study population was 54.2 ± 9.7 years, 58% of patients were female, and the prevalence of subclinical hypothyroidism was 18%. No significant differences were observed between subclinical hypothyroid and euthyroid groups in FIB-4 or NFS values. A weak but statistically significant correlation was observed between TSH levels and the FIB-4 index (r = 0.15, p = 0.034), whereas no significant correlation was found with NFS. In multivariable analysis adjusted for age, sex, body mass index, diabetes mellitus, homeostasis model assessment of insulin resistance (HOMA-IR), and triglyceride-to-high-density lipoprotein (HDL) cholesterol ratio, subclinical hypothyroidism was not independently associated with advanced fibrosis risk. These findings indicate metabolic factors remain the primary determinants of fibrosis risk.Keywords
This publication has 29 references indexed in Scilit:
- Reply to: correspondence regarding “A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement”Journal of Hepatology, 2020
- Subclinical Hypothyroidism and Low-Normal Thyroid Function Are Associated With Nonalcoholic Steatohepatitis and FibrosisClinical Gastroenterology and Hepatology, 2018
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Non-alcoholic fatty liver – Perhaps not so benignJournal of Hepatology, 2015
- Nonalcoholic fatty liver disease: A precursor of the metabolic syndromeDigestive and Liver Disease, 2015
- Non-alcoholic fatty liver disease across the spectrum of hypothyroidismJournal of Hepatology, 2012
- Prevalence of Hypothyroidism in Nonalcoholic Fatty Liver DiseaseDigestive Diseases and Sciences, 2011
- Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2009
- The NAFLD fibrosis scoreHepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006